Literature DB >> 2112158

Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.

M W Mosesson1, D N Fass, P Lollar, J P DiOrio, C G Parker, G J Knutson, J F Hainfeld, J S Wall.   

Abstract

Porcine plasma factor VIII (fVIII) molecules are heterodimers composed of a 76,000-mol wt light chain (-A3-C1-C2) and a heavy chain ranging in molecular weight from 82,000 (A1-A2) to 166,000 (A1-A2-B). Proteolytic activation of fVIII by thrombin results in fVIIIa heterotrimers lacking B domains (A1, A2, A3-C1-C2). In this study, immunoaffinity purified fVIII was further fractionated by mono S or mono Q chromatography to prepare heterodimers containing a light chain and an A1-A2-B heavy chain (fVIII 166/76) or an A1-A2 heavy chain (fVIII 82/76). Mass analysis of scanning transmission electron microscopic (STEM) images of fVIII 166/76 indicated that heterodimers (mass 237 +/- 20 kD) had irregularly globular core structures 10-12 nm across, and frequently displayed a diffuse, occasionally globular to ovoid satellite structure extending 5-14 nm from the core, and attached to it by a thin stalk. Factor VIII 82/76 molecules (mass 176 +/- 20 kD) had the same core structures as fVIII 166/76 molecules, but lacked the satellite structure. These findings indicate that A1-A2 domains of heavy chains and the light chains of the fVIII procofactor molecule are closely associated and constitute the globular core structure, whereas the B domainal portion of heavy chains comprises the peripheral satellite appendage. Factor VIII core structures commonly displayed a finger-like projection near the origin of the B domainal stalk that was also a consistent feature of the free heavy chains (mass 128-162 kD) found in fVIII 166/76 preparations. Factor VIII light chain monomers (mass, 76 +/- 16 kD) were globular to c-shaped particles 6-8 nm across. These chains commonly possessed a v-shaped projection originating from its middle region, that could also be observed at the periphery of fVIII core molecules. Factor VIIIa preparations contained heterotrimers (mass 162 +/- 13 kD) that had the same dimensions as fVIII core structures, lacked the B domainal appendage, and sometimes possessed the same core features as fVIII molecules. Molecular species corresponding to heterodimers (mass, 128 +/- 13 kD) and unassociated subunit chains (40-100 kD) were also observed in fVIIIa preparations, suggesting that heterotrimers have an appreciable tendency to dissociate, a phenomenon that could explain the decay of fVIIIa activity after thrombin activation of fVIII.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112158      PMCID: PMC296667          DOI: 10.1172/JCI114662

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Effects of thrombin treatment of preparations of factor VIII and the Ca2+-dissociated small active fragment.

Authors:  H A Cooper; F F Reisner; M Hall; R H Wagner
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

Review 2.  Mass mapping with the scanning transmission electron microscope.

Authors:  J S Wall; J F Hainfeld
Journal:  Annu Rev Biophys Biophys Chem       Date:  1986

3.  Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII).

Authors:  D D Pittman; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

4.  Subunit structure of thrombin-activated human factor VIIIa.

Authors:  P J Fay
Journal:  Biochim Biophys Acta       Date:  1988-01-29

5.  Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule.

Authors:  D L Eaton; W I Wood; D Eaton; P E Hass; P Hollingshead; K Wion; J Mather; R M Lawn; G A Vehar; C Gorman
Journal:  Biochemistry       Date:  1986-12-30       Impact factor: 3.162

6.  A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.

Authors:  J J Toole; D D Pittman; E C Orr; P Murtha; L C Wasley; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

7.  Subunit structure of thrombin-activated porcine factor VIII.

Authors:  P Lollar; C G Parker
Journal:  Biochemistry       Date:  1989-01-24       Impact factor: 3.162

8.  Molecular characterization of commercial porcine factor VIII concentrate.

Authors:  P Lollar; C G Parker; R P Tracy
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

9.  Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells.

Authors:  R J Kaufman; L C Wasley; A J Dorner
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

10.  Stoichiometry of the porcine factor VIII-von Willebrand factor association.

Authors:  P Lollar; C G Parker
Journal:  J Biol Chem       Date:  1987-12-25       Impact factor: 5.157

View more
  4 in total

1.  Electron microscopy of human factor V and factor VIII: correlation of morphology with domain structure and localization of factor V activation fragments.

Authors:  W E Fowler; P J Fay; D S Arvan; V J Marder
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry.

Authors:  J Spaargaren; P L Giesen; M P Janssen; J Voorberg; G M Willems; J A van Mourik
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

3.  Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors.

Authors:  Claude Négrier; Johannes Oldenburg; Gili Kenet; Shannon L Meeks; Jean-Claude Bordet; Jens Müller; Sandra Le Quellec; Peter L Turecek; Nikola Tripkovic; Yesim Dargaud
Journal:  Res Pract Thromb Haemost       Date:  2022-06-19

4.  Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII.

Authors:  Philip M Zakas; John F Healey; Ian W Smith; David Lillicrap; Pete Lollar
Journal:  Front Immunol       Date:  2020-02-07       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.